VENUSREMNSEVenus Remedies Limited· PharmaceuticalsLowNeutral
Announced Sat, 23 Aug · 16:37 IST

Scrutinizer s report & Voting results of 36th Annual General Meeting

Board & Shareholder Meetings View source PDF

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Venus Remedies Limited held its 36th Annual General Meeting on 22nd August 2025 via video conferencing, and all 10 resolutions set out in the AGM notice were passed with the requisite majority. The resolutions included adoption of audited standalone and consolidated financial statements for FY ending 31st March 2025, ratification of cost auditor remuneration of Rs. 1,10,000 per annum for FY 2025-26, appointment of M/s P. Chadha & Associates as Secretarial Auditor for five years, and re-appointments of Mr. Pawan Chaudhary (Managing Director), Mr. Peeyush Jain (Deputy Managing Director), Mr. Ashutosh Jain (Executive Director), Mr. Akshansh Chaudhary (Executive Director and Director liable to retire by rotation), and Mr. Navdeep Sud (Non-Executive Independent Director). On 15th August 2025, the company had 18,607 shareholders on record, of which 54 attended the AGM (5 from the promoter group and 49 from the public). Voter turnout was mixed, ranging from about 2.4% to 44.15% of outstanding shares depending on the resolution.

Likely market impact

Routine procedural filing confirming smooth conduct of the AGM and continuity of the existing management team and auditor for the next five years. No material business impact for shareholders; the leadership re-appointments provide stability but no new strategic direction is signaled.